Autoimmune diseases, rejection of transplanted organs and grafts, chronic inflammatory
diseases, and immune‐mediated rejection of biologic drugs impact a large number of …

Autoimmune diseases affect many people worldwide. Current treatment modalities focus on
the reduction of disease symptoms using anti-inflammatory drugs which can lead to side …

Abstract Rationale: The FDA-approved Dimethyl Fumarate (DMF) as an oral drug for
Multiple Sclerosis (MS) treatment based on its immunomodulatory activities. However, it also …

Autoreactive lymphocytes that escape central immune tolerance may be silenced via an
endogenous peripheral tolerance mechanism known as anergy. Antigen-specific therapies …

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system and is
considered to be the leading non-traumatic cause of neurological disability in young adults …

Mucosal barrier tissues and their mucosal associated lymphoid tissues (MALT) are attractive
targets for vaccines and immunotherapies due to their roles in both priming and regulating …

A pressing need exists for antigen-specific immunotherapies (ASIT) that induce selective
tolerance in autoimmune disease while avoiding deleterious global immunosuppression …

A pressing need exists for autoimmune disease therapies that act in an antigen-specific
manner while avoiding global immunosuppression. Multivalent soluble antigen arrays …

Autoimmune diseases are believed to be highly dependent on loss of immune tolerance to
self-antigens. Currently, no treatments have been successful clinically in inducing …

The development of biomaterial-based therapeutics to induce immune tolerance holds great
promise for the treatment of autoimmune diseases, allergy, and graft rejection in …